Literature DB >> 16416167

Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder.

Hiroshi Itoh1, Koji Nishijima, Yoshiyuki Kurosaka, Shigeru Takegawa, Masato Kiriyama, Shotaro Dohba, Yasuhiko Kojima, Yasuo Saitoh.   

Abstract

The present study sought to identify the therapeutic efficacy of adjuvant external beam radiotherapy (EBRT) for carcinomas of the extrahepatic bile duct (EHBD) and gallbladder. Twenty-one patients with pathologically verified EHBD carcinoma and 18 patients with gallbladder carcinoma were analyzed retrospectively by Cox regression analysis for predictors of survival. The overall 5-year survival rates after resection were 33% for EHBD carcinoma and 56% for gallbladder carcinoma. The overall 5-year survival rate for EHBD carcinoma was 60% in 8 patients without microscopic residual disease (R0), 15% in 9 patients with microscopic residual tumor (R1), and 0% in 4 patients with macroscopic residual tumor (R2). The overall 5-year survival rate of gallbladder carcinoma patients was also decreased with R status equal to 73%, 40%, and 0% for R0, R1 and R2, respectively. Adjuvant radiotherapy significantly improved the 5-year survival rate in 7 patients with R1 disease of EHBD carcinoma (P = .035), compared with survival in 2 patients who underwent resection alone. However, no significant difference was noted in the 5-year survival rate between the resection plus EBRT group and the resection alone group for gallbladder carcinoma. Multivariate analysis revealed that histopathologic grade (G) was an independent predictor of survival for EHBD carcinoma and that direct invasion of liver parenchyma was a predictor of survival for gallbladder carcinoma. This study suggests that curative resection provides the best survival for patients with EHBD and gallbladder carcinoma, and that radiotherapy may play a beneficial role in controlling local-regional residual EHBD carcinoma tumors. However, new strategies for adjuvant therapy are needed to improve survival in patients with gallbladder carcinoma.

Entities:  

Mesh:

Year:  2005        PMID: 16416167     DOI: 10.1007/s10620-005-3040-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  External radiotherapy and extrahepatic bile duct cancer.

Authors:  R A Tollenaar; C J van de Velde; C W Taat; D Gonzalez Gonzalez; J W Leer; J Hermans
Journal:  Eur J Surg       Date:  1991-10

Review 2.  Future role of radiotherapy as a component of treatment in biliopancreatic cancers.

Authors:  L L Gunderson; M G Haddock; P Burch; D Nagorney; M L Foo; T Todoroki
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

3.  Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer.

Authors:  T Todoroki; T Kawamoto; M Otsuka; N Koike; S Yoshida; Y Takada; S Adachi; H Kashiwagi; K Fukao; K Ohara
Journal:  Hepatogastroenterology       Date:  1999 May-Jun

Review 4.  Surgical treatment in proximal bile duct cancer. A single-center experience.

Authors:  R Pichlmayr; A Weimann; J Klempnauer; K J Oldhafer; H Maschek; G Tusch; B Ringe
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

5.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

6.  The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy.

Authors:  T Kamada; H Saitou; A Takamura; T Nojima; S I Okushiba
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

7.  Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.

Authors:  William R Jarnagin; Leyo Ruo; Sarah A Little; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Raquel Wagman; Leslie H Blumgart; Yuman Fong
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

8.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

9.  Analysis of failure after curative irradiation of extrahepatic bile duct carcinoma.

Authors:  S J Buskirk; L L Gunderson; S E Schild; C E Bender; H J Williams; D C McIlrath; J S Robinow; W J Tremaine; J K Martin
Journal:  Ann Surg       Date:  1992-02       Impact factor: 12.969

10.  Primary carcinoma of the gallbladder. Adjuvant postoperative external irradiation.

Authors:  J F Bosset; G Mantion; M Gillet; E Pelissier; M Boulenger; P Maingon; O Corbion; S Schraub
Journal:  Cancer       Date:  1989-11-01       Impact factor: 6.860

View more
  19 in total

1.  Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis.

Authors:  Clifton D Fuller; Samuel J Wang; Mehee Choi; Brian G Czito; John Cornell; Tania M Welzel; Katherine A McGlynn; Join Y Luh; Charles R Thomas
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

Review 2.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

3.  Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma.

Authors:  Wen-Ke Cai; Jia-Ji Lin; Gong-Hao He; Hua Wang; Jun-Hua Lu; Guang-Shun Yang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 4.  Chemotherapy and targeted therapy for gall bladder cancer.

Authors:  Bhawna Sirohi; Ashish Singh; P Jagannath; Shailesh V Shrikhande
Journal:  Indian J Surg Oncol       Date:  2014-06-03

5.  Therapeutic Potential of Adjuvant Stereotactic Body Radiotherapy for Gallbladder Cancer.

Authors:  Anand Mahadevan; Nergiz Dagoglu; Jennifer F Tseng; Khalid Khawaja; Amy Evenson
Journal:  Cureus       Date:  2015-08-10

Review 6.  Current management of gallbladder carcinoma.

Authors:  Andrew X Zhu; Theodore S Hong; Aram F Hezel; David A Kooby
Journal:  Oncologist       Date:  2010-02-10

7.  Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: a meta-analysis.

Authors:  Xin-Qi Shi; Jing-Yu Zhang; Hua Tian; Ling-Na Tang; Ai-Lin Li
Journal:  J Zhejiang Univ Sci B       Date:  2020-07       Impact factor: 3.066

8.  Selective histopathology in cholecystectomy for gallstone disease.

Authors:  Rohin Mittal; Mark Ranjan Jesudason; Sukria Nayak
Journal:  Indian J Gastroenterol       Date:  2010-04-06

9.  Adjuvant radiotherapy for gallbladder cancer: a dosimetric comparison of conformal radiotherapy and intensity-modulated radiotherapy.

Authors:  Xiao-Nan Sun; Qi Wang; Ben-Xing Gu; Yan-Hong Zhu; Jian-Bin Hu; Guo-Zhi Shi; Shu Zheng
Journal:  World J Gastroenterol       Date:  2011-01-21       Impact factor: 5.742

10.  Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Authors:  Johan Fevery; Chris Verslype; Gillian Lai; Raymond Aerts; Werner Van Steenbergen
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.